On behalf of Pfizer Animal Health, IPSOS Forward carried out a market survey on the EU swine respiratory disease market.
The survey consisted of phone interviews among 617 swine producers in Belgium (69), France (100), Germany (100), Italy (100), the Netherlands (91), Spain (100) and the UK (57). Producers were farm owner/manager or live production manager, and have vaccinated for Mycoplasma hyopneumoniae and/or Circovirus in the last 12 months.
It was shown that the majority of swine producers vaccinate against both Mycoplasma and Circovirus. 67% vaccinate for Mycoplasma and 57% vaccinate for Circovirus. The majority (80%) have added Circovirus to their vaccination schedule rather than replacing M. hyo or PPRS. Respondents do not foresee a significant decrease in M. hyo vaccination in the near future.
About half of producers who use anti-infectives (AIFs) believe that they reduce the impact of SRD, improve overall health and deliver a positive return on investment. The most commonly used AIF to prevent or treat SRD in piglets is Draxxin. 34% use Draxxin, 70% use it to prevent rather than treat SRD in suckling pigs and in nursery pigs Draxxin is used to both prevent and treat SRD.